Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $116.33.
Several analysts have weighed in on BPMC shares. HC Wainwright upped their price objective on shares of Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, June 7th. Stifel Nicolaus increased their price target on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Stephens began coverage on shares of Blueprint Medicines in a research note on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Blueprint Medicines in a research note on Friday, June 28th.
Check Out Our Latest Research Report on Blueprint Medicines
Insider Buying and Selling at Blueprint Medicines
Institutional Investors Weigh In On Blueprint Medicines
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Blueprint Medicines by 0.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after acquiring an additional 145 shares during the period. US Bancorp DE raised its holdings in shares of Blueprint Medicines by 5.2% during the first quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock worth $353,000 after acquiring an additional 183 shares during the period. Van ECK Associates Corp raised its holdings in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Blueprint Medicines by 1.7% during the fourth quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock worth $1,338,000 after acquiring an additional 247 shares during the period. Finally, Triad Wealth Partners LLC acquired a new stake in Blueprint Medicines in the 2nd quarter valued at $27,000.
Blueprint Medicines Price Performance
Shares of Blueprint Medicines stock opened at $114.97 on Friday. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $7.20 billion, a price-to-earnings ratio of -23.90 and a beta of 0.63. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $121.90. The firm’s 50-day moving average price is $107.76 and its two-hundred day moving average price is $95.38.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.32. The firm had revenue of $96.12 million for the quarter, compared to analysts’ expectations of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. On average, equities analysts predict that Blueprint Medicines will post -4.7 earnings per share for the current fiscal year.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Read More
- Five stocks we like better than Blueprint Medicines
- Investing In Preferred Stock vs. Common Stock
- Why This AI Stock is Rising Despite Tech Sell-Off
- Do ETFs Pay Dividends? What You Need to Know
- MarketBeat Week in Review – 7/15 – 7/19
- Why Invest in High-Yield Dividend Stocks?
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.